Johnson & Johnson reports lower mortality with Impella heart pumps and positive Javelin catheter trial results
At the 2026 TCT congress, Johnson & Johnson presented three real‑world analyses of Impella‑supported high‑risk PCI covering 1,379 patients. In‑hospital mortality was 4.7% for 578 patients meeting CHIP‑BCIS3 criteria, 30‑day mortality 6.1% in a 279‑patient European registry, and discharge cardiovascular mortality 3.4% in a 522‑patient U.S. registry, all below the roughly 8% rate reported in the CHIP‑BCIS3 trial. The company also disclosed that its investigational Shockwave Javelin intravascular lithotripsy catheter achieved 93.6% technical success and 93.4% safety at 30 days in a 158‑patient pivotal study.
Why it matters
The company says the lower mortality data could reinforce adoption of Impella in high‑risk PCI and help revive its cardiovascular unit, which contributed about 1.6% of total revenue in the prior quarter. The Javelin results move the device closer to FDA review, but both sets of data are observational and do not immediately change earnings forecasts.
Key facts
- 1Three observational analyses covered a total of 1,379 Impella‑supported high‑risk PCI patients. rttnews.com
- 2In‑hospital all‑cause mortality among 578 PROTECT III patients meeting CHIP‑BCIS3 eligibility was 4.7%, versus an estimated ~8% in CHIP‑BCIS3. rttnews.com
- 3The 279‑patient TRI‑GUARD‑PCI European registry reported 30‑day all‑cause mortality of 6.1% and 180‑day mortality of 7.9%. rttnews.com
- 4The 522‑patient U.S. registry analysis showed cardiovascular mortality of 3.4% at discharge, with estimated 30‑day mortality of 4.7% and 90‑day mortality of 6.5%. rttnews.com
- 5The Shockwave Javelin catheter achieved 93.6% successful lesion crossing (technical success) and 93.4% freedom from major adverse cardiovascular events through 30 days (safety) in a 158‑patient pivotal study. rttnews.com
- 6J&J closed at $273.20, down 0.73% after the announcements. rttnews.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.